Abstract Amyotrophic lateral sclerosis (ALS) is a progressive adult-onset, neurodegenerative disease characterized by the degeneration of upper and lower motor neurons. Over recent years, numerous genes have been identified that promote disease pathology, including SOD1, TARDBP, and the expanded hexanucleotide repeat (GGGGCC) within C9ORF72. However, despite these major advances in identifying genes contributing to ALS pathogenesis, there remains only one currently approved therapeutic: the glutamate antagonist, riluzole. Seminal breakthroughs in the pathomechanisms and genetic factors associated with ALS have heavily relied on the use of rodent models that recapitulate the ALS phenotype; however, while many therapeutics have proved to be significant in animal models by prolonging life and rescuing motor deficits, they have failed in human clinical trials. This may be due to fundamental differences between rodent models and human disease, the fact that animal models are based on overexpression of mutated genes, and confounding issues such as difficulties mimicking the dosing schedules and regimens implemented in mouse models to humans. Here, we review the major pathways associated with the pathology of ALS, the rodent models engineered to test efficacy of candidate drugs, the advancements being made in stem cell therapy for ALS, and what strategies may be important to circumvent the lack of successful translational studies in the clinic.
Introduction
Neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's diseases and motor neuron disease (MND) make up a group of pathologies characterized by the degeneration and/or death of neurons predominantly in the central nervous system (CNS). While these disorders have separate etiologies with distinct morphological and pathophysiological features, they share common neuropathological hallmarks such as impaired protein dynamics with defective protein degradation and aggregation, oxidative stress and free radical formation, impaired bioenergetics, mitochondrial dysfunction, and compromised neuroinflammatory processes [1] . Amyotrophic lateral sclerosis (ALS) is a chronic adult-onset MND that causes death of lower motor neurons in the brainstem and spinal cord and of upper motor neurons in the motor cortex. The resulting motor neuron loss leads to muscle atrophy and weakness, fasciculations, spasticity, and typically death from respiratory failure [2] . Neurons in the prefrontal and temporal cortex are also affected in a proportion of patients with ALS in which degeneration of neurons results in frontal executive dysfunction and concurrent frontotemporal lobar degeneration (FTLD) in approximately 15 % of patients. This is known as ALS with FTLD. ALS affects approximately two individuals per 100,000 per year. While the disease course may vary drastically among patients, once afflicted, the average survival is approximately 3-5 years from symptom onset [1] .
ALS can be classified into two subtypes-familial ALS (fALS) or sporadic ALS (sALS)-which clinically overlap. The disease is most commonly sporadic, with no clear genetic component; however, the association of environmental factors such as heavy metals, pesticides, and excitotoxins, including b-N-methylamino-L-alanine (BMAA) [3, 4] , or epigenetic modifications have been reported. However, 5-10 % of ALS cases are familial, whereby a single genomic DNA mutation results in disease, with most cases having an autosomal dominant pattern of inheritance; x-linked and recessive fALS cases are rare [5] . FALS is associated with mutations in a heterogeneous group of genes. Of the 5-10 % of fALS cases, 20 % have a mutation in the copper-zinc superoxide dismutase 1 (SOD1) gene [6] . Discovered over 20 years ago, this was the first causative gene identified to harbor mutations linked to ALS [7] . Since the discovery, over 155 mutations in SOD1 have been described. This was followed by the discovery of transactivation response DNA-binding protein 43 (TARDBP) involvement in ALS in 2008 [8] . Over the years, there have been seminal discoveries and breakthroughs, including recently identified expanded hexanucleotide repeat (GGGGCC) within the chromosome 9 open reading frame 72 (C9ORF72) gene, which contributes to the most common cause of fALS [9] [10] [11] .
The identification of multiple RNA binding proteins frequently mutated in ALS has placed them at a pivotal point in disease etiopathology and has led to ALS being categorized as an RNA-misprocessing disease. However, despite major recent breakthroughs in identifying genes contributing to ALS pathogenesis driven by a new generation of genomic sequencing technologies (refer to Table 1 ), there remains only one currently approved therapeutic: the glutamate antagonist, riluzole (brand name Rilutek TM ). Riluzole only extends survival by *2 to 3 months, and usually with considerable adverse side effects [12] . Thus, while there remains a major push to identify the remaining genetic factors that underlie ALS, there is an urgent need to convert the genetic understanding we already have into effective disease-modifying treatments for this chronic, debilitating, and lethal disease.
Much of our current understanding of ALS stems from transgenic mouse models that emulate the fALS cases. However, since the development of the first transgenic ALS (SOD1) mouse more than 20 years ago, a cure, or even robust treatment, for ALS (or even for cases of ALS with mutant SOD1) has yet to be achieved. Significant issues face researchers today in the development of a therapeutic agent to treat ALS because the etiology of ALS is highly multifactorial, being associated with impairment of different molecular processes such as oxidative stress, excitotoxicity, and mitochondrial dysfunction. Additionally, it is heterogeneous, with misprocessing of a myriad of RNA binding proteins implicated in the pathogenesis of ALS and, further to this, primary targets of mutant proteins In this review, we summarize some of the known cellular pathways contributing to the pathology of ALS and the pharmacological compounds currently being developed to target these pathways (Fig. 1) . We also examine the available transgenic mouse models and investigate their advantages and drawbacks for shedding insight on ALS pathology. We question whether the mouse models are essentially helping us or is overexpression of a protein driven by an artificial promoter producing misleading outcomes that do not translate well through clinical trials? What are the alternatives, if any? We also analyze some of the ongoing drug developments and clinical trials and examine how these are progressing against a backdrop of broad failure of anti-neurodegenerative disease therapeutics. We also discuss the potential for stem cell therapy to harness disease modeling, drug discovery, and autologous cell-replacement therapies. Finally, we discuss how we can move forward in the development of therapeutics in light of this knowledge to try and make some real advances in the treatment of ALS by the end of the decade.
Cellular Mechanisms of Amyotrophic Lateral
Sclerosis (ALS) Pathogenesis and Drug Targets
Excitotoxicity and Anti-Excitotoxic Agents
Glutamate is the primary excitatory amino acid neurotransmitter in the CNS, produced throughout the brain and spinal cord, primarily in astrocytes and also in neurons and oligodendrocytes. It is indispensable for normal brain functions, including motor function, cognition, memory, and learning [13, 14] . Glutamatergic neuron stimulation causes the release of glutamate into the synapse, where it activates ionotropic and metabotropic glutamate receptors. The excitatory signal is terminated by the clearance of glutamate from the synaptic cleft by glutamate reuptake transporters, the most abundant of which in the CNS is the excitatory amino acid transporter 2 (EAAT2, also known as GLT1). Glutamate-induced excitotoxicity resulting in motor neuron injury is one pathogenic mechanism of ALS [15] . This may result from increased levels of synaptic glutamate, which causes excessive stimulation of glutamate receptors, or by increased sensitivity of the postsynaptic neuron to glutamate, resulting from modifications in neuronal energy homeostasis or glutamate receptor expression [16, 17] . GLT1 is responsible for the clearance of synaptic glutamate, and its knockout in transgenic mice results in neuronal death [18] . A large body of evidence has demonstrated a potential role for glutamate-induced toxicity in ALS. Despite the proliferation of astrocytes, the expression of GLT1 was down-regulated in SOD1 G93A mice with disease progression [19] . Examination of human post mortem ALS brain (motor cortex) and spinal cord tissue also demonstrated profound loss of GLT1 expression compared with controls [20] . As mentioned earlier, riluzole-the only US FDA-approved treatment for ALS-is thought to offer protection against motor neuron injury through excitotoxicity by interrupting glutamatergic transmission and attenuates glutamate concentrations by affecting N-methyl-D-aspartate (NMDA) or a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, exerting an anti-excitotoxicity effect. Another potential mode of action for riluzole is to block inactivated voltage-gated sodium channels [12] . However, this drug has limited therapeutic value, as it only prolongs the ALS patients' life by 3 months [21] . Ceftriaxone, a b-lactam antibiotic, has been shown to protect neurons from apoptosis and increase the gene expression of glutamate transporters, making it a tantalizing candidate to intercept excitotoxicity in ALS [22] . In vivo, in a SOD1 G93A ALS mouse model, this drug displayed efficacy in preventing glutamate neurotoxicity and, when administered at disease onset, delayed the loss of muscle strength and body weight and prolonged survival [22] .
In translational studies, an open trial of 108 ALS patients showed that ceftriaxone did not substantially improve muscle strength and disability scores [23] . However, ceftriaxone was still pursued for clinical trials and was reported to be a safe and tolerable drug for humans in clinical stages I and II. Unfortunately, this drug failed in phase III clinical trials due to a lack of efficacy in increasing length of patient survival or preventing a decline in motor function [13, 24] . This is a classic example of an increasing number of recent studies in mice failing to translate well in humans and raises the issue of inadequate preclinical study design in ALS mouse models. More rigorous therapeutic assessments of these drugs in ALS mouse models need to be implemented and, indeed, many journals and funding bodies now require evidence of careful assessment to show that studies are adequately powered. A related issue is that the majority of drug studies are only performed in animal models on a single inbred genetic background (e.g., C57BL6) and drug efficacy does not always translate to mixed genetic backgrounds [25] .
Oxidative Stress and Anti-Oxidative Agents
Oxidative stress results from an imbalance between the generation of reactive oxygen species (ROS) and their removal, and/or the ability of the biological system to remove or repair ROS-induced damage [26] . This cellular stress-response pathway has gained considerable attention as the potential underlying mechanism of neurodegeneration in ALS because mutations in SOD1, an antioxidant enzyme, can cause fALS.
With thorough investigations of oxidative stress in ALS, it has become apparent that oxidative stress interacts with and potentially impairs other pathophysiological processes contributing to motor neuron injury, including excitotoxicity, mitochondrial dysfunction, protein aggregation, endoplasmic reticulum stress, and changes in cellular signaling in astrocytes and microglia [26] . Analyses of cerebro-spinal fluid (CSF) and human post mortem CNS tissue have shown the presence of biochemical changes as a result of free radical damage or abnormal free radical metabolism, with these changes more robust in ALS/MND cases than in controls [27] [28] [29] . Additionally, elevated levels of oxidative damage to proteins, lipids, and DNA have been found in post mortem tissue from sALS and SOD1-linked fALS cases [27, 30] . Further to this, using human stem cellderived motor neurons combined with RNA sequencing, Kiskinis et al. [31] demonstrated a transcriptional signature of heightened oxidative stress in mutant SOD1-linked ALS. Aberrant RNA metabolism is a key feature of ALS pathogenesis. With this, it is not surprising that oxidation of RNA species has been well documented. In mutant SOD1 mice, increased messenger RNA (mRNA) oxidation was observed in spinal cord motor neurons and oligodendrocytes at early pre-symptomatic stages. RNA species encoding proteins involved in mitochondrial electron transport and protein biosynthesis, folding, and degradation were also highly oxidized. While treatment with the antioxidant vitamin E did not alter survival of SOD1 G93A mice, it did reduce mRNA oxidation, delay disease onset, and improve motor performance during the course of the disease [32] .
Nuclear factor erythroid-2-related factor 2 (Nrf2) is the chief regulator of the antioxidant response and responds to oxidative stress by binding to and upregulating antioxidant response element (ARE) genes [26] . Alterations in Nrf2 expression and dysregulation of the Nrf2 signaling cascade could contribute to the chronic motor neuron degeneration in ALS and other neurodegenerative diseases. Indeed, Nrf2 signaling may be impaired in models of SOD1-related ALS and in the CNS of ALS patients [33] . Therefore, Nrf2 appears as a key neuroprotective molecule in ALS. Recent studies strongly support that the Nrf2 signaling pathway is an important mediator of neuroprotection and therefore exemplifies a promising target for development of innovative therapies against ALS [34, 35] . An antioxidant, Nacetyl-L-cysteine (NAC), improves survival and delays the onset of motor impairment in SOD1 G93A mice [36] . However, a clinical trial for N-acetyl-L-cysteine, administered at 50 mg/kg per day subcutaneously for 12 months (compared with placebo) failed to produce significant differences in survival or changes in decline of motor symptoms after 12 months [37, 38] .
Manganese porphyrin (AEOL10150), an antioxidant and a free radical scavenger has been proven to extend the survival of SOD1 G93A mice when administered at symptom onset, improving motor neuron structure and attenuating astrogliosis [39] . While antioxidant therapies have proven beneficial in mouse models of ALS, they have failed in preclinical trials. Generally, antioxidant trials have been of suboptimal methodological design and quality and, to date, unpromising [40] . There have been numerous small studies for antioxidant therapies in clinical trials implementing agents such as creatine (5-10 g) and selegiline, a selective monoamine oxidase B inhibitor that has some therapeutic benefit in Parkinson's disease (10 mg daily); however, this treatment did not benefit patients, and no significance in survival was evident [41, 42] . With conflicting data from animal models of ALS and poor translational outcomes, this could be attributed to age or strain differences used in studies and, indeed, these need to be scrutinized closely in future studies. Nevertheless, a meta-analysis of drug treatment trials in SOD1 transgenic mouse models of ALS concluded that antioxidants have been the most effective at extending survival among animals treated at symptom onset [43, 44] . Recently, a number of potentially novel antioxidant therapies have been identified; however, these must be pursued with thorough attention to pre-clinical and clinical trial design, pharmacology, and pharmacokinetics [45] [46] [47] . Therefore, ongoing antioxidant clinical trials are warranted and, indeed, offer some hope for the future.
Mitochondrial Dysfunction and Mitochondrial Protective Agents
Mitochondria are the energy producers for the cell and regulate critical cellular pathways such as apoptosis, intracellular calcium homeostasis, and the generation of intracellular free radicals. A large body of evidence indicates impaired mitochondrial function in ALS. This is evident by the high occurrence of mitochondrial DNA mutations in motor cortex tissue from sporadic ALS cases and diminished mitochondrial DNA in muscle and spinal cord in sALS [48, 49] . Aggregation of mutant SOD1 (mSOD1) in mitochondria is a common feature in ALS. Expression of mSOD1 proteins in motor-neuronal cell lines demonstrated the propensity to associate with the mitochondria and form cross-linked oligomers. It was reasoned that their presence causes a shift in the redox state of these organelles and results in impairment of respiratory complexes [50] . The accumulation of mSOD1 at the site of mitochondria may also disrupt the association of cytochrome c with the inner mitochondrial membrane [51] . This suggests a strong link between defective mitochondria due to the toxic function of mutant SOD1 and the pathogenesis of ALS, instigating the search for neuroprotective therapies targeting mitochondria [52] . Impaired mitochondria in ALS is not exclusive to mSOD1 cases. Reports have emerged of mutations in TARDBP, the principle component of ubiquitinated inclusions in ALS to alter mitochondrial dynamics, affecting mitochondrial length and density in neurites from primary motor neurons [53] . Additionally, juxtanuclear aggregates of mitochondria were observed, along with increased levels of fission 1 (Fis1) and phosphorylated dynamin-like protein (DLP1), key components of the mitochondrial fission machinery in TDP-43 transgenic mice [54] .
Candidate mitochondrial modulators have included olesoxime, which promotes survival of mutant motor neurons in vitro, conceivably by targeting the voltage-dependent anion channel (VDAC) and the benzodiazepine receptor [55] . Olesoxime was used in a double-blinded, randomized, placebo-controlled trial over the course of 18 months in combination with riluzole. However, although olesoxime was well tolerated by patients, it did not show a significant beneficial synergistic effect in ALS patients concomitantly treated with riluzole, with no significance in survival observed [56] . Dexpramipexole, noted to function as a mitochondrial membrane stabilizer, showed promise in animal models of ALS by increasing the life span of human SOD1 G93A (hSOD1) mice by 7 days. In double-blinded phase II trials, it was safe and well tolerated by ALS patients [24] ; however, in human phase III trials, dexpramipexole proved negative because it failed to meet its primary efficacy endpoint [57] . Despite the failures, there is still promise, with ongoing candidates being investigated in animal models of ALS. One promising candidate is the synthetic antioxidant [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl]triphenylphosphonium methane sulfonate, which is analogous to the natural antioxidant coenzyme Q10 and known as MitoQ. In a SOD1
G93A mouse model of ALS, MitoQ 500 lM was administered in the drinking water of mice from early symptom onset. It significantly prolonged the survival of mice, slowed the progression of ALS symptoms, and attenuated nitroxidative damage in the nervous system [46] . These studies support the role of mitochondrial dysfunction in the progression of ALS.
Indeed, mitochondria-targeted antioxidants may be of pharmacological use for ALS treatment, and MitoQ holds hope as a treatment strategy for ALS.
Neuroinflammation and Anti-Inflammatory Therapies
ALS is characterized by the death of motor neurons in the brain and spinal cord and is accompanied by a neuroinflammatory response that is denoted by microglial activation and T-cell infiltrates localized at affected regions in the CNS. Therefore, inflammatory mechanisms and immune reactivity are hypothesized to play a role in the pathogenesis of ALS. Significant levels of microgliosis have been observed in the spinal cord of ALS patients at autopsy, with T-cell infiltrates found in close proximity in affected brain regions, including the primary motor cortex and motor nuclei of the brain stem [58] . Conspicuously, patients with sALS have been reported to have increased levels of circulating inflammatory (CD16?) monocytes in peripheral blood that positively correlated with increased levels of lipopolysaccharide (LPS), an inducer of M1 activation in macrophages in plasma [59, 60] . Although neuroinflammation is often considered a secondary effect rather than a cause of neurodegeneration in ALS patients and in ALS mouse models, numerous studies have demonstrated that regulation of the inflammatory response in mSOD1 mice alters disease progression [61, 62] . In ALS mice and human patients, there is significant elevation in tumor necrosis factor (TNF)-a and Fas ligand (FASL) immunoreactivity, hallmarks of proinflammatory responses [63] . This body of evidence supports the strong contention that neuroinflammation is a key feature of ALS and plays an important role in ALS pathogenesis. Anti-inflammatory therapies to date have been discouraging. The same notion exists for anti-inflammatory agents as for anti-oxidant agents, in that they produce adequate outcomes in animal models of ALS, for example, delaying motor neuron degeneration and prolonging survival [64] . However, they have failed in human pre-clinical trials. Minocycline, a second-generation tetracycline that has anti-inflammatory properties, was shown to delay motor neuron degeneration and increase survival in different mSOD1 mouse models of ALS [64, 65] . Minocycline had an effect directly on motor neurons by decreasing apoptosis through a decrease in the release of cytochrome c and also decreasing the level of microglial activation and proliferation in mSOD1 mouse models of ALS [65] . In a randomized placebo-controlled phase III trial for minocycline, 412 patients were assigned to receive placebo or minocycline in doses up to 400 mg/day for 9 months. Measurement of drug efficacy included rate of change in the revised ALS functional rating scale (ALSFRS-R), manual muscle testing (MMT), quality of life, survival, and safety. Patients who received minocycline displayed a faster decline in MMT score and greater mortality during the treatment period than patients receiving placebo, with minocyclinealarmingly-having adverse and harmful effects on patients with ALS [66] . With contrasting and adverse effects from mice to humans, reflections from this study have prompted further questioning of the ALS mouse model: whether it resembles the ALS patients' clinical profile and whether it is suitable as a model on which to base clinical trials. Other factors to be considered are dosage and dosing schedules, with varying reports of minocycline being neurotoxic or neuroprotective depending on the dose [67] . Along with cytokines and other inflammatory factors, cyclooxygenase (COX)-2 is involved in the inflammatory process in the CNS, and is highly expressed in astrocytes and neurons. Inhibition of COX-2 was shown to have beneficial properties in animal models of ALS. The administration of the COX-2 inhibitor and anti-inflammatory agent celecoxib significantly delayed the onset of weakness and weight loss, prolonged survival of ALS mice, and significantly attenuated astrogliosis and microglial activation [68] . Celecoxib was safe and well tolerated in a double-blinded, placebo-controlled clinical trial in 300 ALS patients who received celecoxib 800 mg/day or placebo for 12 months. However, celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, ALSFRS-R, or affect survival; therefore, it had no beneficial effect to patients [69] . Table 2 summarizes the drug trials discussed and clinical trial outcome.
Transgenic Mouse Models of ALS and Their
Impact on Drug Development
The use of animal models allows researchers to administer therapeutics before, during, and after symptom onset to assess the efficacy of potential treatments for ALS. Undeniably, mouse models have shed considerable light on the cell pathways involved in the pathogenesis of ALS, have recapitulated the key histopathological and biochemical features of ALS, and have identified targets that are promising candidates to intercept in ALS pathogenesis [91] . Unfortunately, while mice show behavioral and motor changes that are loosely reminiscent of ALS, these changes are also seen in most mouse models of neurodegeneration. Due to the limited brain structure, the mouse is restricted in how it can express neuronal impairment compared with the complex neurodegenerative disease phenotypes in humans.
In such cases, are we really seeing ALS symptoms or simply symptoms of a 'sick' mouse? In addition, it is evident that it is difficult to transfer the dosing schedules and regimens implemented in mouse models to humans, as it is not possible to treat patients for symptoms before they arise, therefore perplexing therapeutic regimens in clinical trials. Next, we discuss the available transgenic mouse models used in testing the efficacy of ALS therapeutics, their advantages and disadvantages, and which model/s are evidently appropriate to continue using in the thorough investigations for a therapeutic treatment for ALS. No single animal model seamlessly reflects the clinical and pathological profile of ALS patients; however, continuing studies from the most relevant models will provide a better understanding of the pathogenesis of ALS.
Superoxide Dismutase 1
Since the discovery of SOD1 mutations in fALS, the SOD1 G93A transgenic mouse model has been developed, expressing approximately 20-24 copies of human mutant SOD1, driven by the human SOD1 promoter [92] . This was followed by the development of over 20 SOD1 transgenic models engineered to recapitulate the ALS phenotype. SOD1 transgenic mouse lines display characteristic ALSlike motor neuron degeneration, with hind limb paralysis, muscle atrophy, loss of spinal motor neurons, damage to astrocytes, attenuated GLT-1 expression, and axonal and mitochondrial dysfunction [79, 92, 93] . The most widely used SOD1 animal model is the SOD1 G93A transgenic model; these mice display disease onset and survival correlated with transgene expression level. Additional factors that contribute to development of ALS symptoms in these mice include genetic background and gender [94, 95] . Other models have been developed, such as SOD1 G37R and SOD1
G85R
, that have given further insight into ALS pathology.
The SOD1 G37R transgenic mice, which retain full SOD1 activity, accumulate to 3-12 times the endogenous levels in the spinal cord, and the levels of the mutant protein influence the age of onset. Low expression of SOD1 G37R is restricted to lower motor neurons; however, high copy number causes severe abnormalities with the presence of membrane-bound vacuoles that may be a result of degenerating mitochondria [79] .
The SOD1 G85R mouse model has been reported to cause MND at low expression levels, and this appeared to be mediated by direct damage of astrocytes and attenuated GLT-1 expression [93] . Analysis of various SOD1 models have identified cell pathways implicated in the pathology of ALS, including excitotoxicity, mitochondrial dysfunction, oxidative stress, and neuroinflammation (Fig. 1) .
Numerous drug targets found to be effective in the SOD1 G93A transgenic model failed in clinical trials in humans, including ceftriaxone, vitamin E, NAC, manganese porphyrin, dexpramipexole, and MitoQ. Another classic example of poor translational outcomes was testing minocycline in two SOD1 mutant models (G93A and G37R). Three independent studies tested the efficacy of this drug with positive outcomes in the two models, but subsequent clinical trials were negative [64, 65, 90] .
As the majority of pre-clinical studies have heavily relied on the SOD1 G93A transgenic model, confounding issues have been identified. First, this model has substantial overexpression of mutant SOD1 to recapitulate the ALS phenotype. In addition, it has rapid disease onset. An alternative model to consider is the SOD1 G93Adl ; this model has reduced copy number, and onset of disease-like symptoms is delayed and shows slower progression [96] . However, it is imperative to consider the underlying issue-that mutations in SOD1 only account for a small proportion of total ALS cases (approximately 2 %); therefore, therapeutics that demonstrate encouraging results in SOD1 models may not be appropriate for the majority of fALS or sALS cases [97] . Despite the poor translational outcomes, transgenic mouse models overexpressing mutant SOD1 have been pivotal to our progress and major advances in identifying molecular pathways implicated in ALS, such as oxidative stress, mitochondrial dysfunction, and glutamate excitotoxicity [19, 44] , and have formed the basis of much of our knowledge of the underlying pathophysiology. These models have formed the backbone for the development of new treatments and remain a good model to unravel the complexity of ALS and develop therapeutic interventions for its treatment.
TDP-43
The discovery of TDP-43 as the chief protein constituent of cytoplasmic inclusions in motor neurons led to a prominent role for TDP-43 in ALS pathogenesis. TDP-43 is posttranslationally modified, being heavily ubiquitinated in cytoplasmic inclusions in motor neurons of affected ALS patient brains and spinal cords [98, 99] . The redistribution of TDP-43 in the cytoplasm is associated with concomitant loss of normal diffuse nuclear TDP-43 staining in inclusion-bearing cells. This reinforces a likely nuclear loss-offunction model of TDP-43, promoting toxicity in ALS. Numerous studies have identified missense mutations in the C-terminal region in fALS and sALS cases and, to date, over 40 mutations in TARDBP have been identified. The identification of TARDBP mutations has led to the development of a number of transgenic mouse models that express either wild-type (WT) or mutant TDP-43. These models recapitulate ALS pathology with protein fragmentation and aggregation, reactive gliosis, neuronal loss, and reduced survival.
Mouse Prion Promotor, Murine Thy-1.2 Promoter, and Calmodulin-Dependent Protein Kinase II Promoters
Akin to SOD1 transgenic mouse models, development of disease phenotypes in TDP-43-ALS transgenic mouse models is related to the promoter used and the level of transgene expression. The first published transgenic TDP-43 mouse model was the A315T transgenic mouse with expression of the transgene driven under control of the mouse prion promoter (mPrp), with inherent toxic properties. At threefold above endogenous protein levels, mutant TDP-43 caused loss of upper motor neurons and concomitant axonal degeneration, and paralysis and death by 22 weeks of age [100] . Further analysis of these mice revealed that they succumb to gut obstruction, which explains their early mortality [101] . This symptom is caused by transgene expression in the myenteric plexus of the gut, possibly due to activity of the promoter outside the CNS, and is therefore, not an ideal model for the study of potential therapeutic treatments [102] .
The mPrp has also been used to drive transgene expression of WT or Q331K or M337V mutant TDP-43 [71] . This study demonstrated that the mutant but not WTexpressing mice developed age-dependent progressive motor axon degeneration, motor neuron death, and muscle atrophy. These changes occurred without the loss of TDP-43 in nuclei and accumulation of TDP-43 aggregates. These studies suggest that overexpression of mutant TDP-43 increases its toxicity in vivo. Indeed, overexpression of WT or mutant TDP-43, for example TDP-43 M337V , under the control of the mPrp often induces early lethality in transgenic mice [103] . Therefore, consideration of TDP-43 transgene expression regulated by human TDP-43 endogenous promoter may be more feasible to elicit age-related neurodegeneration and motor dysfunction mimicking ALS patients. As such, endogenous human TDP-43 promoters expressing mutant TDP-43 (A315T or G348C) have been developed and display TDP-43 aggregation, cytoplasmic TDP-43 overexpression, and truncated TDP-43 expression in the CNS of transgenic mice [97, 104] . It also manifests with cognitive and motor dysfunction during aging, which recapitulates the course observed in ALS patients [105] .
Some groups have also developed transgenic mice expressing mutant or WT TDP-43 driven under the murine Thy-1.2 promoter (mThy1.2). This promoter can drive expression of TDP-43 exclusively in neurons of the CNS. Analysis of the neuronal populations shows that postnatal TDP-43 overexpression in all neurons results in the formation of neuronal intranuclear inclusions (NII) and neuronal cytoplasmic inclusions (NCI) in layer V of the anterior cortex, and truncation of TDP-43 [105] [106] [107] . Overexpression of TDP-43 under the calmodulin-dependent protein kinase II (CaMKII) promoter triggers WT or mutant TDP-43 overexpression in the forebrain. This transgenic model elicits similar TDP-43 proteinopathy as seen in FTLD and ALS patients, exhibiting cognitive decline from 8 weeks of age and deficits in long-term potentiation of hippocampal neurons with concomitant cytoplasmic TDP-43 inclusion formation and loss of nuclear TDP-43 [108] .
The latter models expressing TDP-43 transgene under the mPrp, mThy1.2 and CaMKII promoters may be ideal to study TDP-43 biology and pathomechanisms, and provide evidence for the toxic functions and mislocalization of TDP-43 in ALS. It is evident that there is variation in the phenotypes exhibited between models according to the promoter and expression levels of transgenes. No TDP-43 model is flawless; however, the models engineered have enabled a thorough understanding of TDP-43 biology in ALS, which is significant in terms of drug design and therapeutic intervention.
Fused in Sarcoma (FUS)
The identification of TARDBP mutations in ALS sparked the identification of mutations in the FUS gene from ALS patients [8, 72] . FUS belongs to the FET (FUS/TLS, EWSR1, and TAF-15) family of DNA/RNA-binding proteins, is a multifunctional, predominantly nuclear protein, and is ubiquitously expressed. Analysis of large ALS cohorts has established that mutations in FUS account for approximately 4 % of fALS cases and 1 % of sALS cases [109] . Transgenic mice engineered to overexpress FUS include HA-tagged human WT FUS driven under control of the mPrp [110] , mice expressing mutant FUS harboring R521C mutation and lacking a nuclear localization signal (NLS) [111] , rats that conditionally express human WT or mutant FUS transgene under a tetracycline response element (TRE) [112] , and transgenic rats that express mutant FUS under the CaMKII promoter plus a TRE [113] .
Transgenic mice overexpressing HA-tagged WT human FUS have been shown to develop an aggressive phenotype with an early-onset tremor. Homozygous transgenic mice also displayed progressive hind limb paralysis and death by 12 weeks [110] . Biological changes in FUS were evident, with motor neurons in the spinal cord displaying robust cytoplasmic expression of FUS, with globular and skeinlike FUS-positive and ubiquitin-negative inclusions. Cytoplasmic FUS inclusions were also evident in cortical neurons of these mice, in the absence of neuronal loss and gliosis [97, 110] . Somatic brain transgenic (SBT) mice expressing adenoassociated virus human WT or mutant FUS (R521C or lacking a NLS; D14) postnatally in neuronal cells of the mouse brain were engineered to investigate the role of FUS in the pathogenesis of ALS. Mutant but not WT FUS had aberrant subcellular redistribution, which correlated with disease mutation and clinical severity of the mutations in patients. While no neuronal death or motor defects were evident, neuronal cytoplasmic inclusions analogous to those seen in post mortem ALS tissue were observed in cortical neurons [111] . This model recapitulates the neuropathology of FUS in FUS-linked ALS, and supports the contention that mutations in FUS promote its accumulation in the cytoplasm and is ideal to investigate the pathomechanisms of FUS in ALS. Transgenic rats engineered to express WT human or mutant (R521C) FUS under stringent control by doxycycline was developed by Huang et al. [112] . Mutant FUS transgenic rats developed progressive paralysis akin to ALS, requiring euthanasia at 10 weeks, which was not evident in transgenics expressing WT FUS. Degeneration of motor axons and a significant loss of neurons in the cortex and hippocampus also occurred with concomitant ubiquitin aggregation and glial reaction in mutant FUS transgenics; however, a minimal loss of spinal motor neurons was evident. While transgenic rats that overexpressed the WT human FUS had no motor phenotype at young ages, they developed deficits in spatial learning and memory, significant loss of cortical and hippocampal neurons, and ubiquitin aggregation and gliosis at 1 year of age [97, 112] . This model suggests that expression of WT FUS can cause neuronal cell death; however, mutant FUS is more toxic to neurons. Expression of mutant FUS in rats driven by the CaMKII promoter and using TRE from 30 days of age resulted in impaired spatial learning and memory by 5 weeks of age. By 8-9 weeks, there was loss of neurons in the dentate gyrus and frontal cortex. This simultaneously occurred with abnormal neuritic branching, altered dendritic spine density, and progressive Golgi fragmentation and mitochondrion aggregation [113] . Pathologically, FUS and ubiquitin-positive aggregates were observed in the cytoplasm of neurons, interestingly with the absence of endogenous TDP-43. Additionally, there was no co-localization of ubiquitinated aggregates with fragmented Golgi or aggregated mitochondria. This model is ideal to investigate a mechanistic study of cortical dementia in FTLD [113] .
Clearly, there are differences in the phenotypes presented by the transgenic FUS rodent models. Problems with early lethality in transgenic rats expressing mutant FUS (R521C) regulated by doxycycline that require euthanasia at 10 weeks of age and display incomplete loss of motor neurons makes it difficult to emulate the ALS phenotype in these mice. In addition, mice developed by Verbeeck et al. [111] , did not show signs of motor defects or succumb to disease, with the confounding issue of viral delivery of mutant FUS and inadequate expression compared with transgenic models. Overall, these rodent models are essentially worthy to investigate the pathomechanisms of FUS in ALS; however, it may be time to develop a FUS transgenic model that recapitulates expression of endogenous FUS in humans. This may be via a knock-in mouse model, whereby endogenous mouse Fus is replaced by mutant Fus; this may replicate the ALS phenotype in humans and may circumvent the issues we face today with the current FUS models.
C9orf72
In 2011, two groups independently identified the largest genetic cause of ALS and FTLD as a repeat expansion of the hexanucleotide sequence GGGGCC (G 4 C 2 ) in the C9ORF72 gene [9, 10] . With thorough investigations of C9ORF72 in various patient cohorts, it has come to light that expansions in the gene contribute up to *40 to 50 % of fALS and *10 % of sALS cases [73] . hnRNP A1, hnRNPA2/B1, and hnRNP A3 proteins have also been recently described as interacting factors of C9ORF72 hexanucleotide RNA [11] , which may impede the nuclear role of these proteins, contributing to the pathology associated with C9ORF72 expansions. There are multiple hypotheses describing the underlying mechanisms by which the repeat expansion leads to neuropathology, including loss of function caused by haploinsufficiency of the endogenous C9ORF72 protein product or gain of function induced by the formation of RNA foci in neuronal nuclei that sequester important RNA-binding proteins. This mechanism is also supported by the production of toxic dipeptide repeat (DPR) proteins by repeat-associated non-AUG translation (RAN) of the repeat [11] .
The confounding technical issue associated with mouse models of C9ORF72 repeats is that in human cases, there are [1000 repeats [114] ; however, mouse models express 80 repeats at most [115] . Nevertheless, as discussed below, the development of these mice still proves useful to investigate the pathomechanisms associated with C9ORF72 or for testing potential therapeutics targeting G 4 C 2 expansions.
A gain-of-function mouse model of C9orf72 was developed by Hukema et a. in 2014 [115] . A spatially and temporally inducible transgenic mouse model expressing 80 G 4 C 2 repeats was engineered. This transgene is regulated by the TRE promoter and inducible in response to doxycycline. Expression of 80 G 4 C 2 repeats lead to the formation of ubiquitin-positive inclusions in the striatum and the cuneate nucleus of mouse brain; however, no TDP-43-positive inclusions were evident after 12 weeks of doxycycline treatment. The mice did not develop any obvious behavioral phenotype and showed no cell loss or DPR pathology, which has been postulated as a toxic product from translation of the repeat [11] . However, this model may be suitable for investigating the effects of the repeats without toxicity elicited by DPRs.
Most recently, Chew et al. [74] reported on a C9orf72 transgenic mouse model that, to date, closely recapitulates the phenotype of C9ORF72-associated ALS/FTD [74] . Adeno-associated viral vector was employed for the expression of either 2 (a number found in healthy people) or 66 G 4 C 2 repeats, lacking an ATG start codon in the CNS of mice [74] . RNA fluorescence in situ hybridization revealed that, in transgenic mice expressing 66 G 4 C 2 repeats, RNA foci were detected in nuclei containing transcribed repeats, indicative of those observed in C9ORF72 ALS/FTD patients, which was not evident in control counterparts. Brains (frontal cortex and hippocampus) of 6-month-old mice contained inclusions of poly(Gly-Pro), poly(Gly-Ala), and poly(Gly-Arg) DPRs, and were positive for phospho TDP-43 immunoreactivity. At 6 months of age, (G 4 C 2 ) 66 mice developed cortical neuron loss and exhibited behavioral and motor deficits [74] . Indeed, G 4 C 266 mice should prove useful in deciphering pathomechanisms associated with the C9ORF72 repeat expansion [74] . This model is valuable for testing potential therapeutics targeting G 4 C 2 expansions such as the use of anti-sense oligonucleotide technology. These molecules are short oligo-nucleotide sequences that are able to interfere with RNA processing. This is a promising strategy for treating ALS associated with G 4 C 2 expansions, as they have been shown to attenuate intranuclear RNA foci and mitigate the sequestration of important RNAbinding proteins, which are known to promote neuronal toxicity [116] .
Stem Cell Therapies for ALS: Neural Stem
Cells, Mesenchymal Stem Cells, and Induced Pluripotent Stem Cells
The development of cell-based models for ALS has shed light on the molecular pathways associated with the disease and has provided the much-needed alternative to rodent models of ALS for potentially high-throughput drug screenings. Preclinical studies have been carried out transplanting different types of cells in mouse models of ALS, such as neural stem cells (NSCs) and mesenchymal stem cells (MSCs). MSCs are bone marrow (BM) cells that can be expanded ex vivo to produce large numbers of cells and can readily differentiate into mesodermal cell derivatives [117] . Their potential therapeutic mode of action is thought to be associated with the release of protective factors, including trophic factors, anti-inflammatory cytokines, and immunomodulatory chemokines released from transplanted cells even distal to the site of injection. Following intravenous injection into SOD1
G93A ALS mice, a significant delay in disease onset (14 days), increased lifespan (18 days), and delayed disease progression was observed compared with untreated mice [118] . Phase I clinical trials for direct intraparenchymal transplantation of MSCs into ALS patients reinforced the safety of MSC transplantation into the spinal cords of ALS patients; however, the MSC transplant did not appear to slow disease progression in the majority of patients [119, 120] .
NSCs are multipotent self-renewing stem cells that have the ability to differentiate into neurons, astrocytes, and oligodendrocytes. Results from a dual grafting paradigm of NSCs into cervical and lumbar spinal cords of SOD1 G93A rats demonstrated that rats with live NSCs grafted at two spinal levels lived 17 days longer and disease onset in dually grafted animals was delayed by 10 days compared with control counterparts that received dead NSC grafts [121] . Results from a phase I trial with the same NSI-566RSC cells concluded that transplantation of these human NSCs into the lumbar and even cervical spinal cord of ALS patients is feasible, safe, and well-tolerated, and disease progression did not accelerate in any patient [122] . These results have supported future trial phases to examine therapeutic dosing and efficacy.
Induced pluripotent stem cells (IPSCs), which possess unique properties such as self-renewal and differentiation into multiple neural cell subtypes including neurons, motor neurons, astrocytes, and oligodendrocytes, among others, can be used to harness disease modeling, drug discovery, and autologous cell-replacement therapies. Motor neurons generated from IPSCs derived from patient skin fibroblasts with familial or sporadic forms of ALS have provided a highly innovative technique to model the disease [123] . Importantly, this technique allows researchers the opportunity to develop cell subtypes from ALS patients with known genotypes and phenotypes. However, they do have their limitations, such as variability and undergoing epigenetic modifications during reprogramming [124] . IPSCs carrying the TDP-43 M337V mutation have been shown to reproduce several key aspects of TDP-43-related proteinopathies, including reduced cell survival, and features of TDP-43 accumulation [125] . IPSCs may be ideal for the study of disease mechanisms and for drug screening. The availability of ALS disease-specific cells will allow researchers the unprecedented opportunity to investigate the mechanism and cause of disease in a human model system [126] . Hope remains that stem cell therapy will facilitate high throughput drug screening, and stem cells may eventually express enough complexity (i.e., 'organ on a chip') to dispel the need for animal studies altogether. Immense effort has gone into engineering transgenic mice to dissect the molecular basis of ALS disease pathology and to trial candidate therapeutics for treatment. However, researchers today are still faced with the complexity and heterogeneity of ALS, which makes it all the more difficult to target the underlying pathology of the disease. We have seen that transgenic mouse models that recapitulate the ALS phenotype have no doubt been beneficial in determining the pathomechanisms associated with ALS and have verified the role of candidate proteins that have been identified by in vitro studies. While candidate drugs have proved effective in mice, e.g., prolonging life and rescuing motor deficits, they have not proven successful in human patients [56, 69] . This conundrum may be addressed by researchers investing their research efforts in mouse models that tick many boxes when it comes to paralleling the ALS phenotype in humans. Indeed, the recent C9ORF72 mouse model ticks most and perhaps all the boxes, displaying RNA foci, DRPs, TDP-43 inclusions, cortical neuron loss, and exhibiting behavioral and motor deficits with no signs of early lethality [74] . Furthermore, the high prevalence of C9ORF72 mutations in fALS suggests that mouse models replicating this phenotype will be the most beneficial for identifying drug targets for disease intervention. Additionally, the development of sophisticated in vitro models will provide crucial information about the intracellular modulations of disease-relevant proteins and hence a better understanding of the disease. However, these sophisticated models come with limitations that hamper their novelty and unique capabilities. While several in vitro models capture some key features of ALS, the significance of results may not reflect the complex human phenotype given the relative simplicity of in vitro models. Therefore, to counteract these inherent limitations, results generated from in vivo and in vitro models should be combined to better understand and characterize the ALS phenotype. In future, researchers should also focus on testing potential drugs in multiple animal models, preferably in multi-center trials-as is becoming the norm for human clinical trialsand should also ensure the trials are adequately powered. Combination therapy with drugs acting in synergy in appropriately powered studies should also be considered, to circumvent the lack of efficacy of the drugs administered alone in humans. Therefore, not ruling out drugs that showed promise in mice but failed in human clinical trials may provide new avenues for treatment strategies. In conjunction, drug candidates should be tested in different genetic backgrounds to determine the effects of genetic variability on therapeutic efficacy [127] . Differing mouse genetic backgrounds have their advantages and disadvantages, therefore researchers need to thoroughly consider their choices based on the experimental paradigm and objective [128] . It is becoming increasingly important to develop effective therapies for patients with ALS and, with the right tools and collaborations, the disappointing failures may come to an end in the not too distant future.
